Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

46results about How to "Increase in motility" patented technology

Smooth muscle controller

A method of promoting the healing of a lesion in a smooth muscle, comprising selecting a smooth muscle portion having a lesion and applying a non-excitatory electrical field to the portion, which field reduces the mechanical activity of the portion.
Owner:METACURE

Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Owner:IMMATICS BIOTECHNOLOGIES GMBH

System and method for determining sleep and sleep stages of a person

The present invention relates to a system and method for determining sleep, sleep stage and / or sleep stage transition of a person, including heart rate detecting means configured for detecting a heart rate of the person, movement detecting means configured for detecting a movement of a part of the body of the person, where the detected movement is caused by a skeletal muscle of the body, recording means configured for recording the detected heart rate and the detected movement of the part of the body, heart rate classifying means configured for classifying the recorded heart rate of the person into at least one heart rate class at least one heart rate variability class, movement classifying means configured for classifying the recorded movement into at least one movement class, and determining means configured for determining sleep, a sleep stage, a sleep stage transition and / or a sleep event of the person based at least partially on the at least one heart rate class and the at least one movement class.
Owner:V WATCH

Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Owner:IMMATICS BIOTECHNOLOGIES GMBH

Gastric Bypass Devices and Methods

Devices and methods for achieving weight loss in obese and morbidly obese patients are disclosed. The invention combines a gastric and / or small bowel bypass (in which ingested food bypasses the stomach and, optionally, at least a portion of the small bowel) and a satiety device in the form of one or more expandable chambers, that tend to induce a feeling of satiety after the patient has consumed a relatively small amount of food. This combination of gastric and / or small bowel bypass and satiety structure may be delivered and removed using minimally invasive procedures such as an endoscope. In some instances, the gastric and / or small bowel bypass device itself can form the satiety structure. In other devices, the gastric bypass may be independent of the satiety structure (which may be provided as one or more expandable chambers).
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES

Immediate release pH-independent solid dosage form of cisapride

The present invention concerns oral dosage forms of some particular salts of cisapride, more particularly cisapride-(L)-tartrate, cisapride-(D)-tartrate, cisapride-sulfate, or cisapride citrate, which avoid drugfood interaction and which allow comedication of agents that increase the pH of the stomach. The invention particularly relates to solid oral dosage forms suitable for rapid dissolution. The present invention also concerns tablets which can be prepared via direct compression.
Owner:JANSSEN PHARMA NV

In vitro cell-based methods for biological validation and pharmacological screening of chemical entities and biologicals

This patent describes a novel in vitro cell-based method for biological validation and pharmacological screening of drugs, new chemical entities (NCEs) and biologics, which is predictive of in vivo testing for efficacy and adverse events in patients, as occurs in clinical trials. The same method can be used to create an in vitro cell-based assay to identify the ‘right marketed medication for the right patient’ (personalized medicine), and to identify responders / non-responders in ongoing clinical trials with NCEs. In addition this approach can be used to identify new indications for existing medicines and new indications for NCEs that were unsuccessful in their intended uses.
Owner:MOHANLAL RAMON W

Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans

A method is disclosed for treating idiopathic asthenozoospermia and improving sperm quality which comprises orally or parenterally administering to a subject in need thereof a combination preparation comprising either an admixture of or separately packaged L-carnitine and acetyl L-carnitine, or a pharmacologically acceptable salt thereof, in molar ratios ranging from about 4.0:1 to 1:1.5.
Owner:SIGMA TAU IND FARMACEUTICHE RIUNITE SPA

Culture substrate, culture sheet, and cell culture method

Disclosed is a culture sheet which enables technology in which three-dimensional tissues with uniform diameter are formed without applying chemicals to the surface of a culture substrate. A plurality of holes are formed on the culture sheet of the substrate, and nanopillars capable of controlling the adhesiveness or migration of a cell are formed on a culture surface that serves as the bottom surface of each of the holes. The culture surface of each of the holes having a structure in which a partition wall is provided, wherein, by forming the internal nanopillars in the vicinity of the center of each of the holes, the interaction of the disseminated cells can be limited to uniform the size of the three-dimensional structures of the cells to be formed.
Owner:HITACHI LTD

A3AR agonists for the treatment of inflammatory arthritis

The present invention concerns a method for the treatment of inflammatory arthritis, and in particular rheumatoid arthritis, by administering to the subject specific low dosages of N6-(3-iodobenzyl)-adenosine 5'-N-methyl-uronamide (IB-MECA) and 2-chloro-N6-(3-iodobenzyl)-adenosine-5'-N-methyl-uronamide (CL-IB-MECA).
Owner:CAN-FITE BIOPHARMA LTD

Polar organic extract of eurycoma longifolia

The present invention provides a composition including a polar organic extract of Eurycoma longifolia and a fraction derived from the polar organic extract, said composition comprising of quassinoids, coumarins, their glycosides, analogues and derivatives, which exhibits bioactivity of increasing spermatozoa production and spermatozoa quality in terms of morphology and motility, as well as increasing testosterone synthesis and release from cells of males. The extraction method of E. longifolia plant to produce the polar organic extract, and the subsequent purification to produce the fraction of polar organic extract containing the quassinoids, coumarins, their glycosides, analogues and derivatives, and uses for manufacturing a preparation for infertility treatment are also provided. The fraction of polar organic extract containing the quassinoids, coumarins, their glycosides, analogues and derivatives is formulated for medical applications via several routes of administration.
Owner:UNIVERSITI SAINS MALAYSIA

Pharmaceutical compositions including alginates and methods of preparing and using same

InactiveUS7776839B2Effective healingPromoting endocytic or/ruffling activityBiocideDigestive systemAlginic acidPharmacology
A pharmaceutical composition is provided for use in the healing of cells containing about 0.0001 percent weight per volume (% w / v) to about 2% w / v of an alginic acid or a salt of alginic acid having a molecular weight in the range of greater than about 250,000 to about 1,000,000, provided that if the composition additionally contains an alginic acid or a salt of alginic acid having a molecular weight in the range of about 20,000 to about 250,000, it is present in an amount of less than 1% w / w. The use of the pharmaceutical composition for the healing cells in a mammal, preferably mucosal cells is also provided.
Owner:RECKITT BENCKISER HEALTHCARE (UK) LTD

Quasi-spherical orbital implant

A quasi-spherical orbital implant that comprises an off center conical elongation toward its posterior and medial aspects. The conical elongation mimics the natural shape of an orbit. The implant comprises a number of holes and tunnels for suturing the patient's eye muscles and tissue to the implant. A number of hollow voids in the implant serve to progressively host the formation of tissue which secures the implant to the muscles and covering tissue and helps to prevent migration after the sutures have dissolved. The anterior portion of the implant has a number of details which key with the prosthetic eye and help improve its stability and motility.
Owner:OCULO PLASTIK

Production methology for frozen dairy

A reduced dose inseminate and method for producing and using such reduced dose inseminate to fertilize the eggs of a female animal by artificial insemination with fewer sperm cells than compared with conventional dose inseminates.
Owner:XY

A3AR agonists for the treatment of inflammatory arthritis

The present invention concerns a method for the treatment of inflammatory arthritis, and in particular rheumatoid arthritis, by administering to the subject specific low dosages of N6-(3-iodobenzyl)-adenosine 5′-N-methyl-uronamide (IB-MECA) and 2-chloro-N6-(3-iodobenzyl)-adenosine-5′-N-methyl-uronamide (CL-IB-MECA).
Owner:CAN-FITE BIOPHARMA LTD

Dopamine 3 receptor agonist and antagonist treatment of gastrointestinal motility disorders

InactiveUS20060116350A1Increase in motilityIncrease gastrointestinal tract motility and gastric emptyingBiocideNervous disorderDopamine receptorGastrointestinal motility disorder
The invention discloses that systemic activation of dopamine 3 receptor (D3R) significantly delays gastric emptying in rat, suggesting that D3R plays an important role in the regulation of gastric motility. Specific D3R antagonist, nafadotride, was shown to partially reverse the effect of dopamine on gastric emptying. The invention also discloses that D3R agonists and antagonists can be used to treat gastrointestinal motility disorders.
Owner:BOARD OF RGT UNIV OF TEXAS SYST THE

Quasi-spherical orbital implant

A quasi-spherical orbital implant that comprises an off center conical elongation toward its posterior and medial aspects. The conical elongation mimics the natural shape of an orbit. The implant comprises a number of holes and tunnels for suturing the patient's eye muscles and tissue to the implant. A number of hollow voids in the implant serve to progressively host the formation of tissue which secures the implant to the muscles and covering tissue and helps to prevent migration after the sutures have dissolved. The anterior portion of the implant has a number of details which key with the prosthetic eye and help improve its stability and motility.
Owner:OCULO PLASTIK

Device for photo-therapy of grover's disease and use thereof

ActiveUS20190054310A1Uniform light coverageDesired radiationLight therapyDiseaseSerum rash
The present invention provides a photo-therapy device and its use for treatment of skin conditions such as rashes or similar dermatological conditions that are exhibited by Grover's disease or other diseases which are associated or co-existent with Grover's disease. The treatment includes exposure of the subject's affected skin and preferably the entire body with blue LED light to improve skin status by stimulating body's immune system to reduce itching, blotchiness and skin discomfort.
Owner:TCELLERATE LLC

Methods for determining prognosis for breast cancer patients

Described herein are methods for treating breast cancer and for providing a prognosis for metastatic-free survival of breast cancer patients. Aspects relate to treating a patient determined to be at high risk for developing or having metastatic breast cancer comprising administering adjuvant or neoadjuvant therapy to the patient determined to be at high risk for developing or having metastatic breast cancer, wherein the patient was determined to be at high risk for developing or having metastatic breast cancer by determining that the expression level of RKIP was reduced and / or the expression level of one or more of HMGA2, CCL5, TN-FR2, GRN, and CCL7 was elevated in a biological sample from the patient compared to a control non-metastatic tissue sample.
Owner:UNIVERSITY OF CHICAGO

Method and system for treating patients

There is provided a system and method for treating a patient by administering a predetermined sequence of adjustments to a patient's body. Unlike the unstructured or random application of adjustments used in prior art chiropractic treatments, the treatment sequences and provided for herein unlock function of dysfunctional joint systems in a manner analogous to a combination lock mechanism. Disciplines that may utilize embodiments of the present invention include chiropractic, naturopaths, sports medicine, physical therapy, professional and collegiate trainers, as well as aspects of veterinary medicine. Through applications of the method of the present invention, patients may receive a predetermined number of treatment applications, and have long-lived or substantially permanent results from the treatment without the need for ongoing adjustments to spine or other body structures.
Owner:SWANSON ANDREW

Therapeutic and/or preventive agent for dyschezia

The present invention provides a therapeutic and / or preventive agent for defecation dysfunction, which is suitable for continuous medication and comprises as an active ingredient a compound of Formula (1) or a pharmaceutically acceptable salt thereof: (wherein R1 represents a C1-C6 alkyl group and R2 represents a C1-C6 alkyl group). The above erythromycin derivative of Formula (1) has an improving effect on defecation dysfunction; and this improving effect on defecation dysfunction leads to acceleration of normal defecation, unlike a laxative. Further, the above compound of Formula (1) is also suitable for long-term clinical use because of its weaker antibacterial action than erythromycin. Thus, the present invention provides an agent having a safe and potent therapeutic and / or preventive effect on defecation dysfunction.
Owner:CHUGAI PHARMA CO LTD

Sperm Delivery Device

Sperm Delivery Device with a cup shaped sperm storage vessel, the side walls of the vessel having plurality of retaining receptacles, a resilient disk shaped portion integral with and parallel to the base of the sperm storage vessel, a thin closure membrane that dissolves at body temperature in a moist environment, and a closure ring having downwardly extending prongs that penetrate the retaining receptacles of said side walls of said sperm storage vessel that traps said closure membrane between the top of said sperm containing vessel and the underside of said closure ring. A preferred embodiment includes wherein said dissolvable closure sheet is made of gelatin or some other non-harmful dissolvable ingredient.
Owner:BAYLISS KIM R

Fertility-enhancing cooling seat

A fertility-enhancing cooling seat for lowering temperatures of human testicles so as to increase sperm quality and quantity. The cooling seat includes: a top flexible portion and a base portion; a bottom flexible portion coupled to the top flexible portion, the bottom flexible portion forming a seal with the base portion, portions of the bottom flexible portion and portions of the top flexible portion defining isolated cooling cells with cooling-cell volumetric spaces; a phase-change material located in the cooling-cell volumetric spaces, the phase-change material configured to change from a solid phase to a liquid phase at a first temperature and that is configured to change from a liquid phase to a solid phase at a second temperature that is lower than the first temperature. At least one of the isolated cooling cells defines a diameter that is larger than a diameter of the other of the cooling cells.
Owner:ABRAMSON DAVID L +2

Method for screening cancer therapeutic agent using galectin-3, GSK-3β, and fascin-1

Disclosed is a method for screening a novel cancer therapeutic agent. The cancer therapeutic agent exhibits down-regulation of galectin-3 and fascin-1 or interferes with the interaction between galectin-3 and GSK-3β.
Owner:NAT CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products